Long-Term Safety Data Reassures Type 1 Diabetes Prevention Researchers

A major safety review of immunotherapy trials spanning up to 18 years found no increased risks from experimental type 1 prevention treatments. The findings clear the path for continued research into delaying disease onset.

cure researchbeta cellsadvancements

Key takeaways

Researchers tracked over a decade of safety data from 14 randomized immunotherapy trials with thousands of participants at risk for or living with type 1 diabetes
No significant differences emerged between treatment and placebo groups in hospitalizations, serious infections, new allergies, autoimmune disease, or cancer
This is a safety milestone, not a cure—these therapies delay type 1 onset but do not stop or reverse the disease
Long-term safety evidence is crucial for moving prevention research forward and informing treatment decisions

A Reassuring Long-Term Safety Check

For researchers working on ways to prevent or delay type 1 diabetes, safety is paramount. A new analysis published in *Diabetes Care* offers important reassurance. Scientists reviewed data from 14 randomized controlled trials of immunotherapy—experimental treatments designed to modulate the immune system—tracking participants for up to 18 years. Some had type 1 diabetes already; others were at high risk but not yet diagnosed.

The headline: no red flags. When researchers compared people who received active therapy to those who received placebo, they found no meaningful differences in self-reported health outcomes, severe low blood sugar episodes, hospitalizations, serious infections, new allergies, newly diagnosed autoimmune diseases, or cancer.

What This Safety Data Does—and Doesn't—Mean

It's crucial to be clear about what this finding shows. This research is about safety, not efficacy. It does not demonstrate that these immunotherapies stop, reverse, or cure type 1 diabetes. What it does show is that on long-term follow-up, people who received experimental immune-modulating treatments did not experience the serious adverse effects researchers were monitoring for.

For the field, that matters enormously. Before investing further in prevention trials and before patients can consider these approaches, safety evidence must be solid. This analysis provides that foundation, allowing prevention research to move forward with confidence.

New Research on Insulin Management

While immunotherapy research focuses on delaying type 1 onset, other studies are exploring ways to ease day-to-day diabetes management. A newly recruiting clinical trial is testing tirzepatide—a medication currently approved for type 2 diabetes and weight management—in adults with type 1 diabetes. Early research suggests tirzepatide may lower appetite, slow digestion, reduce insulin needs, and smooth blood sugar spikes after meals.

The trial, which will enroll 105 adults across Canada and Switzerland, is investigating whether tirzepatide could reduce or eliminate the need for carbohydrate counting when using an insulin pump. Carbohydrate counting remains one of the most challenging aspects of type 1 management, even for people using advanced pumps and continuous glucose monitors. This research is still in early stages, and results are not yet available.

Evidence label

Origin: YouTube / T1D Pulse (Video report). Evidence: Video report, corroborated with 1 indexed study. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.